A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD [gastro-oesophageal reflux disease]

Trial Profile

A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD [gastro-oesophageal reflux disease]

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2010

At a glance

  • Drugs Esomeprazole; Lansoprazole; Pantoprazole
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Apr 2010 Primary endpoint 'Time with intragastric pH greater than 4' has been met.
    • 23 Apr 2010 Results published in Alimentary Pharmacology and Therapeutics.
    • 28 Oct 2008 Results have been reported at the 73rd Annual Scientific Meeting of the American College of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top